PIL against Covaxin trial on 2-18 age group: HC seeks Centre’s stand

By: |
May 19, 2021 11:51 AM

A bench of Chief Justice D N Patel and Justice Jyoti Singh issued notice to the Centre and Bharat Biotech seeking their stand by July 15 on the petition.

covid vaccineThe court declined to pass any interim order staying the permission, granted on May 12, for clinical trials as sought by the petitioner, Sanjeev Kumar. (Representational image)

A PIL to set aside the permission granted by the Drugs Controller General of India to Bharat Biotech for conducting the phase II/III clinical trial of its Covaxin COVID-19 vaccine on the 2-18 age group was heard on Wednesday by the Delhi High Court which sought the Centre’s stand.

A bench of Chief Justice D N Patel and Justice Jyoti Singh issued notice to the Centre and Bharat Biotech seeking their stand by July 15 on the petition.

The court declined to pass any interim order staying the permission, granted on May 12, for clinical trials as sought by the petitioner, Sanjeev Kumar.

The trial will be conducted on 525 healthy volunteers. In the trial, the vaccine will be given by intramuscular route in two doses at day 0 and day 28.

Covaxin, which has been indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), is being used on adults in India’s ongoing COVID-19 vaccination drive.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1COVID-19: Active cases drop to 74,735 in Kerala; 6,664 new cases, 281 deaths
2China to start vaccinating children to age 3 as cases spread
3Dengue cases in Delhi cross 1,000-mark; over 280 fresh cases in one week